Background. The benefit of the combination of serum galactomannan (GM) assay and polymerase chain reaction (PCR)-based detection of serum Aspergillus DNA for the early diagnosis and therapy of invasive aspergillosis (IA) in high-risk hematological patients remains unclear.
Conclusions. A combined monitoring strategy based on serum GM and Aspergillus DNA was associated with an earlier diagnosis and a lower incidence of IA in high-risk hematological patients.
Clinical Trials Registration. NCT01742026.
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Invasive aspergillosis (IA) is the most common invasive fungal disease among patients with hematological malignancies and recipients of allogeneic hematopoietic stem cell transplant (allo-HSCT) [1] [2] [3] [4] [5] . Although the administration of mold-active antifungal prophylaxis and the prompt initiation of empirical therapy are effective strategies, such approaches may lead to drug-to-drug interactions, side effects, and overuse of antifungals [6] .
The management of the high-risk hematological patients has evolved significantly with the advent of new diagnostic methods [7] [8] [9] . An increasing number of studies have assessed the role of detecting Aspergillus DNA in clinical samples by polymerase chain reaction (PCR) [10] [11] [12] [13] [14] [15] [16] , overall suggesting that this method might be more accurate for the diagnosis of IA than conventional culture or serum galactomannan (GM) assay [17, 18] .
Although the combination of serum GM and PCR assays has shown to perform better in terms of sensitivity and negative predictive values [11, 14, 19] , the potential advantage of a diagnostic-driven strategy incorporating both biomarkers remains to be demonstrated. We hypothesized that the serial detection of Aspergillus DNA in combination with serum GM quantification might lead to an earlier guided antifungal therapy and, ultimately, decrease the odds of developing invasive disease. The present trial was aimed at comparing the performance of a combined GM and PCR assay-based vs a GM assay-based monitoring strategy for the early diagnosis and therapy of IA in high-risk patients.
METHODS

Study Population and Setting
This open-label, parallel-group, randomized trial (ClinicalTrials.gov identifier NCT01742026) was performed between February 2011 and September 2012 in 13 centers throughout Spain. Patients (≥18 years) with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission induction therapy for newly diagnosed or relapsed or refractory disease and patients undergoing allo-HSCT were potentially eligible. Exclusion criteria included the diagnosis of IA within 6 months prior to or at enrollment, the receipt of antifungal therapy with anti-Aspergillus activity within 30 days prior to or at enrollment, and a history of hypersensitivity to azoles. Fluconazole was the only antifungal prophylaxis permitted, and no antimold prophylaxis (ie, extended-spectrum triazoles, echinocandins, or polyenes) was initiated during the study period. Patients could be enrolled only once in the study. The local ethics review committees approved the study protocol, and written informed consent was obtained from each patient.
Study Design and Intervention
Patients were randomized at the time of initiating chemotherapy or on day 1 posttransplant in a 1:1 ratio to 1 of 2 arms: GM-PCR group (experimental) or GM group (control). In an attempt to ensure roughly equal numbers in both arms, an independent statistician performed the procedure by using a computergenerated schedule of randomly permuted blocks. Once the site investigator had obtained the patient's consent, phone confirmation of the allocated group was provided. Monitoring was started from the initiation of the remission induction regimen in AML/MDS patients or from day 1 in allo-HSCT recipients. Serum GM and Aspergillus species quantitative real-time PCR (rtPCR) assays were performed twice weekly (on Mondays and Wednesdays) until neutrophil recovery reached ≥0.5 × 10 3 cells/mm 3 for AML/MDS patients, or until days 180 or 100 for allo-HSCT recipients with or without graft-vs-host disease (GVHD), respectively. The results of both GM and rtPCR assays were provided to the attending physicians of patients allocated into the GM-PCR group; in the GM group, only the results of the GM assay were provided. In both groups, these results were available within 24-48 hours from sampling. When the result of at least 1 of the tests informed to the clinicians turned to be positive (ie, serum GM and/or rtPCR in the GM-PCR group and solely the former in the GM group), ordering a thoracic high-resolution computed tomography (HRCT) scan was mandatory and an antifungal agent with activity against Aspergillus species had to be initiated, even if the HRCT scan revealed no radiological signs suggestive of IA according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria [20] (Figure 1 ). Of note, the rtPCR results generated from the GM group had no influence on the clinical management of these patients or on the decision of whether to order an imaging study. Febrile neutropenia episodes were managed with broad-spectrum antibiotics according to the local practice at each center. Attending physicians were allowed to order additional HRCT scan examinations whenever they deemed clinically necessary (even in the absence of any positive monitoring result). Empirical antifungal therapy had to be prescribed after 72 hours of the onset of refractory febrile neutropenia, even if no evidence of IA was present, and subsequently, the patient's withdrawal from the study was mandatory. Nevertheless, the overall duration of the empirical course of therapy was included within the analyses of antifungal consumption (secondary outcome). Diagnosis of "proven" or "probable" IA was also a criterion for patient's withdrawal. Due to its design, the intervention could not be blinded to patients, attending physicians, or investigators. However, laboratory technicians who performed the monitoring assays were blinded to the intervention and all the study outcomes were reviewed by an independent adjudication committee (further details available as Supplementary Material).
Study Outcomes and Follow-up
The primary outcome was the cumulative incidence of proven or probable IA according to the EORTC/MSG criteria [20] . Secondary outcomes included all-cause and proven or probable IA-attributable mortality; proven or probable IA-free survival; cumulative incidence of any EORTC/MSG category of IA ( possible, probable, or proven); and antifungal consumption. The follow-up period extended from the date of first monitoring until 30 days after the resolution of neutropenia for AML/MDS patients, or until days 210 or 130 days for allo-HSCT recipients with or without GVHD, respectively. 
Serum GM and rtPCR Assays
The serum GM assay was performed in the clinical laboratories of each center using the Platelia Aspergillus GM enzyme immunoassay kit (Bio-Rad, Madrid, Spain), and was considered as positive in presence of ≥2 consecutive samples with optical density (OD) indexes between 0.5 and 0.7 or a single sample with an OD index ≥0.7. The detection of Aspergillus DNA in serum was performed by means of a quantitative rtPCR marked with molecular beacons that detects in a multiplex format all Aspergillus species belonging to A. fumigatus, A. terreus, and A. flavus complexes/sections, as previously described [21] [22] [23] and in keeping with the requirements drawn by the European Aspergillus PCR Initiative [24] (further details available as Supplementary Material). To increase the predictive positive value, an rtPCR assay result was considered positive in presence of ≥2 consecutive positive samples [25] . In case of a first single positive result, no earlier confirmatory assay was ordered, but subsequent sampling was repeated according to the abovementioned schedule.
Study Definitions
IA was classified as proven, probable, or possible according to the EORTC/MSG criteria [20] . Definitions for early (diagnostic-driven), targeted, and empirical therapy are shown in Table 1 . Other definitions used in the study were based on accepted criteria [26, 27] and are available in the Supplementary Material.
Statistical Analysis
Details on sample size calculation are provided as Supplementary Material [5, 21, 28] . Study outcomes were primarily analyzed according to per-protocol (PP) principle. In addition, intentionto-treat (ITT) analyses were also performed to examine the robustness of the efficacy results. Qualitative variables were expressed as absolute and relative frequencies. Quantitative data were shown as the mean ± standard deviation or the median with range or interquartile range (IQR). Categorical variables were compared using the χ 2 test or Fisher exact test, whereas Student t test or Mann-Whitney test were applied for continuous variables. Outcomes were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Survival curves were generated according to the Kaplan-Meier method and compared between groups by the log-rank test. All tests were 2-tailed and P values <.05 were deemed significant. Statistical analysis was performed using SPSS software, version 15.0 (SPSS Inc, Chicago, Illinois).
RESULTS
Patient Disposition and Baseline Characteristics
Overall, 224 patients were initially screened for eligibility, 219 of which (97.8%) were enrolled and underwent randomization (ITT population). Four patients did not receive the allocated intervention and 12 patients were further excluded due to major protocol violations, resulting in 96 and 107 patients analyzed in the GM-PCR and GM groups, respectively (PP population) ( patient flow diagram available in Supplementary Figure 1 ). Both arms were overall well balanced, although the duration of neutropenia within the subset of AML patients was longer in the GM-PCR group (P = .006; Table 2 ).
Positivity Rates for GM and rtPCR Assays
The intensity of monitoring was similar in both arms (median of 8 monitoring points per patient). Throughout this period, 23.9% of patients in the GM-PCR group had ≥1 positive rtPCR result compared to 14.0% in the GM group (P = .070). Of 19 patients who tested positive at least once in the 2 assays (8 in the GM-PCR group and 11 in the GM group), the positivity of the rtPCR preceded that of the GM assay in 8 cases (42.1%) by a median interval of 5.5 days (IQR, 2.5-12.25 days). Conversely, the GM assay was the first to turn positive in 7 cases (36.8%) by a median interval of 6 days (IQR, 2-7 days). Patients in the GM-PCR group were more likely to have a thoracic HRCT scan examination, in most cases ordered due to a positive monitoring test (Table 3) . A detailed description of the reasons for ordering such imaging tests and their contribution to diagnosis is available as Supplementary Figure 2 .
Occurrence of Proven or Probable IA (Primary Outcome)
The cumulative incidence of the primary study outcome was significantly lower in the GM-PCR group (4.2% [4/96] vs Table 4) . A positive rtPCR assay result preceded or coincided with that of the GM assay in 50.0% (9/18) of patients with proven or probable IA, whereas detection of serum GM preceded rtPCR in 27.8% (5/18) ( Table 5 ). Of note, the rtPCR monitoring remained negative in 4 patients eventually diagnosed with probable IA within the GM group (details are provided in Supplementary Table 1 .
Secondary Study Outcomes
Proven or probable IA-free survival was significantly longer in the GM-PCR group (log-rank test P = .027; Figure 2 ). In contrast, we found no differences in the cumulative incidence of IA of any EORTC/MSG diagnostic category (13.5% [13/96] Forty-seven patients received empirical antifungal therapy after a median interval of 13 days (IQR, 8-28 days) . Patients in the GM-PCR group were less likely to receive either empirical (P = .038) or targeted therapy (P = .015) as compared to the GM group. Early therapy was more common in the GM-PCR group (P < .0001), with a positive rtPCR assay triggering the initiation of such an approach in most cases (18/19 [94.7%] ). There were no differences in the overall duration of antifungal therapy (Table 6 ).
All-cause mortality did not significantly differ between groups (13.5% [13/96] in the GM-PCR group vs 15.9% [17/107] in the GM group; OR, 0.83 [95% CI, .38-1.81]; P = .695). No differences were found either for proven or probable IA-attributable mortality (Table 6 ). These findings remained unchanged when the analysis was restricted to the ITT population or stratified by underlying condition (data not shown).
DISCUSSION
Previous experiences indicate that Aspergillus DNAemia may precede the release of fungal GM into the bloodstream [19, 21] , which suggests that DNA detection can offer advantages in the early diagnosis and preemptive therapy of IA. In accordance with this rationale, the application of the combined approach based on the detection of both serum GM and Aspergillus DNAemia in high-risk patients not receiving antimold prophylaxis resulted in a relative risk reduction of 68.1% in the primary study outcome ( proven or probable IA).
It should be noted that, similarly to previous trials on highrisk patients [29] [30] [31] , only probable and proven forms of IA were considered as primary outcomes. Because the sensitivity of the PCR method was presumed to be higher than that of the GM assay, we expected a priori that the number of HRCT scans triggered by a positive result would be increased in the GM-PCR group. Thus, the chance to find a radiological image suggestive of IA in the absence of validated mycological criteria -it should be noted that the detection of Aspergillus DNA by PCR has not been recognized so far as a diagnostic criterion by the EORTC/MSG [20] -could be increased among these patients and, in turn, their odds of being diagnosed with possible IA, skewing the results against the intervention arm.
By applying the combined strategy, we were able to reduce by 7 days the median interval elapsed from the start of monitoring to the diagnosis of IA. In preliminary studies, it has been shown that PCR positivity is able to anticipate that of GM assay by 2-3 weeks [11, 12, 19] . Differences in kinetics of both biomarkers may underlie these observations [32] . Surprisingly, the PCR monitoring was persistently negative in 4 patients who eventually developed IA in the control group. All of them received the Positive rtPCR preceding positive GM 3 3
Simultaneously positive rtPCR and GM 0 3 Positive GM preceding positive rtPCR 1 4
Positive GM, rtPCR always negative 0 4
Abbreviations: GM, galactomannan; PCR, polymerase chain reaction; rtPCR, real-time polymerase chain reaction.
diagnosis of probable disease as per EORTC/MSG criteria based on the presence of host factors, radiological findings, and serum GM positivity. We hypothesize that the high rate of falsepositive results with the GM assay [8, 9, 28] and the lack of reliability of our PCR technique to detect species belonging to complexes or sections other than A. fumigatus, A. terreus, and A. flavus might explain this discrepancy, although the possibility of false-negative results in the latter test should also be recognized. The potential advantage in terms of sensitivity from using other samples (ie, bronchoalveolar lavage) for rtPCR monitoring remains to be explored. The combined GM and PCR-based strategy led to a reduction in the use of empirical and targeted antifungal therapy as compared to the conventional approach. On the other hand, early (diagnostic-driven) therapy was more common in the GM-PCR group, mainly due to the earliness of diagnosis exhibited by the rtPCR assay. Such finding might be interpreted as suggesting that the early detection of Aspergillus DNA and therapy ultimately prevented the development of fully established angioinvasive forms. In keeping with this, only 17.4% of patients in the GM-PCR group with a positive rtPCR were finally diagnosed with probable or proven IA compared with 82.3% of those in the control group with a positive GM assay. Overall, these results could indicate that the monitoring for both serum GM and Aspergillus DNAemia might provide a better guidance for antifungal treatment by identifying earlier subclinical stages of the infection.
Previous studies have shown that the implementation of PCR-based monitoring may reduce the use of empirical antifungal therapy [10, 33] . Morrissey et al recently demonstrated that a biomarker-based diagnostic strategy (serum PCR and GM assays) in high-risk hematological patients leads to a reduction in the use of empirical therapy compared to the standard approach based on culture and/or histology [14] . Our trial provides further insight by means of a head-to-head comparison of the utility of both biomarkers in the clinical decision-making process. Had the results for the rtPCR assay been available for clinicians in the GM group, 12.9% [4/31] of patients who received empirical therapy would have benefited from avoiding unnecessary treatment or from advancing its initiation.
Only 5 of the deaths observed in this trial were attributable to IA, resulting in an overall case-fatality rate (27.8%) similar to that in recent studies [2, 4, 5, 14, 34] . Although earlier diagnosis and initiation of therapy might have resulted in a better outcome [35] -as suggested by the nonsignificant trend observed toward a decreased IA-related mortality in the GM-PCR group-it should be stressed that the sample size of our trial was not powered to detect differences in any of the secondary outcomes.
This study has several limitations. Most notably, intergroup differences in the PCR positivity rates could suggest that both arms were not entirely comparable in their baseline risk of IA. In accordance, within the subset of AML patients, the neutropenia was more prolonged in those allocated to the GM-PCR group, whereas the presence of other disparities that remained undetected due to inadequate statistical power cannot be excluded. Nevertheless, such an imbalance should have biased the results against the intervention arm. Conversely, the number of patients with a positive GM assay was slightly lower in the GM-PCR group, although this finding may be explained by the effect of the earlier administration of antifungal therapy once Figure 2 . Proven or probable invasive aspergillosis-free survival (Kaplan-Meier curves) in both study groups ( per-protocol population) (log-rank test P = .027). Abbreviations: GM, galactomannan; IA, invasive aspergillosis; PCR, polymerase chain reaction.
Aspergillus DNAemia was detected, which could have prevented fungal antigen from being released into the bloodstream during the angioinvasion process. Although we jointly analyzed AML patients and allo-HSCT recipients, the pathogenesis of IA in both types of host is not entirely comparable. Our trial was insufficiently powered to detect potential differences in mortality or subgroup analyses. Finally, the unblinded design raises the potential for bias, the direction of which is not straightforward. Indeed, some clinicians could have been prone to rely on the high sensitivity of the PCR and, therefore, to perform closer surveillance in patients with a positive result, whereas others might have felt more comfortable with the conventional, long-standing GM-based strategy and have underestimated to some extent the positive predictive value of the PCR assay.
In conclusion, this is the first trial to directly compare the serial detection of serum GM and Aspergillus DNA with the conventional approach solely based on the GM assay in high-risk hematological patients. Through the earlier diagnosis and initiation of antifungal therapy, the tested strategy was able to significantly decrease the incidence of proven or probable IA. Our results suggest that the PCR should be used to complement, rather than replace, the serum GM assay as the basis of a diagnostic-driven strategy for preventing IA. Further studies are needed to evaluate whether this intervention would offer additional advantages over the increasing use of mold-active antifungal prophylaxis.
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